REGENERON PHARMACEUTICALS, INC. Quarterly Report for Q1 Ended Mar 31, 2016

Summary

Regeneron Pharmaceuticals, Inc. (REGN) reported strong top-line growth in its first quarter 2016 filing, with total revenues increasing to $1.20 billion from $869.6 million in the prior year period. This substantial growth was primarily driven by a significant increase in net product sales, particularly from EYLEA, which saw U.S. sales rise to $780.9 million from $541.1 million in Q1 2015. Collaboration revenues from Sanofi and Bayer also showed healthy growth, indicating the continued strength of key partnerships. The company's net income more than doubled to $165.7 million, or $1.45 per diluted share, compared to $76.0 million, or $0.66 per diluted share, in the first quarter of 2015. This improved profitability reflects not only the robust revenue growth but also increased operating expenses, largely due to expanded research and development and commercialization activities. Despite increased R&D spending, the company's financial performance demonstrates a positive trajectory driven by its core products and expanding pipeline.

Key Highlights

• 1Total revenues increased by approximately 38% year-over-year to $1.20 billion.
• 2Net income more than doubled, reaching $165.7 million ($1.45 per diluted share) compared to $76.0 million ($0.66 per diluted share) in the prior year quarter.
• 3EYLEA net product sales in the U.S. grew significantly, increasing by over 44% to $780.9 million.
• 4Sanofi and Bayer collaboration revenues also saw substantial increases, contributing to overall top-line growth.
• 5Research and development expenses rose significantly to $470.1 million, reflecting continued investment in the company's extensive pipeline.
• 6The company ended the quarter with $604.2 million in cash and cash equivalents, and $800.2 million in marketable securities.
• 7Significant progress was reported in key late-stage clinical programs, including dupilumab for atopic dermatitis and asthma.

Frequently Asked Questions